Comparison of Anticoagulant and Anti-Inflammatory Responses Using Enoxaparin Versus Unfractionated Heparin for Transesophageal Echocardiography-Guided Cardioversion of Atrial Fibrillation††A list of participating clinical sites appears in the Appendix.

American Journal of Cardiology

Volumn 102, Issue 7, 2008, Pages 842-846

  Hoppensteadt, Debra ^a   Fareed, Jawed ^a   Klein, Allan L ^b   Jasper, Susan E ^b   Apperson Hansen, Carolyn ^b   Lieber, Elizabeth A ^b   Katz, William E ^c   Malouf, Joseph F ^d   Stoddard, Marcus F ^e   Pape, Linda A ^f  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF LOUISVILLE   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; C REACTIVE PROTEIN; ENOXAPARIN; HEPARIN; PROTHROMBIN ANTIBODY; THROMBIN ANTITHROMBIN COMPLEX; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CARDIOVERSION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ANTITHROMBIN III; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTRIC COUNTERSHOCK; ENOXAPARIN; FEASIBILITY STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PEPTIDE HYDROLASES; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 52349104985     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.05.025     Document Type: Article

References (17)

1. Klein A.L., Jasper S.E., Katz W.E., Malouf J.F., Pape L.A., Stoddard M.F., Apperson-Hansen C., Lieber E.A., and ACUTE II Steering and Publications Committee for the ACUTE II Investigators. The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: Assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study. Eur Heart J 27 (2006) 2858-2865
2. Broze Jr. G.J., Girard T.J., and Novotny W.F. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 29 (1990) 7538-7546
3. Hoppensteadt D.A., Walenga J.M., Fasanella A., Jesje W., and Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 77 (1996) 175-185
4. Hirsh J., and Raschke R. Heparin and low-molecular-weight-heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl (2004) 188S-203S
5. Zhao L., Zhang Z., Kolm P., Jasper S., Lewis C., Klein A., Weintraub W., and ACUTE II Investigators. Cost in the use of enoxaparin compared with unfractionated heparin in patients with atrial fibrillation undergoing a transesophageal echocardiography-guided cardioversion (from Assessment of Cardioversion Using Transesophageal Echocardiography [ACUTE] II randomized multicenter study). Am J Cardiol 101 3 (2008) 338-342
6. Stellbrink C., Nixdorff U., Hofmann T., Lehmacher W., Daniel W.G., Hanrath P., Geller C., Mugge A., Sehnert W., Schmidt-Lucke C., Schmidt-Lucke J.A., and ACE (Anticoagulation in Cardioversion Using Enoxaparin) Study Group. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion Using Enoxaparin (ACE) trial. Circulation 109 (2004) 997-1003
7. Chung M.K., Martin D.O., Sprecher D., Wazni O., Kanderian A., Carnes C.A., Bauer J.A., Tchou P.J., Niebauer M.J., Natale A., and Van Wagoner D.R. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104 (2001) 2886-2891
8. Aviles R.J., Martin D.O., Apperson-Hansen C., Houghtaling P.L., Rautaharju P., Kronmal R.A., Tracy R.P., Van Wagoner D.R., Psaty B.M., Lauer M.S., and Chung M.K. Inflammation as a risk factor for atrial fibrillation. Circulation 108 (2003) 3006-3010
9. Montalescot G., Bal-dit-Sollier C., Chibedi D., Collet J.P., Soulat T., Dalby M., Choussat R., Cohen A., Slama M., Steg P.G., et al., ARMADA Investigators. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol 91 (2003) 925-930
10. Oldgren J., Fellenius C., Boman K., Jansson J.H., Nilsson T.K., Wallentin L., and Siegbahn A. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease. J Intern Med 258 (2005) 420-427
11. Tyrrell D.J., Horne A.P., Holme K.R., Preuss J.M., and Page C.P. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 46 (1999) 151-208
12. Gaffney A., and Gaffney P. Rheumatoid arthritis and heparin. Br J Rheumatol 35 (1996) 808-809
13. Bowler S.D., Smith S.M., and Lavercombe P.S. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 147 (1993) 160-163
14. Dwarakanath A.D., Yu L.G., Brookes C., Pryce D., and Rhodes J.M. "Sticky" neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 37 (1995) 585-588
15. Petitou M., Herault J.P., Bernat A., Driguez P.A., Duchaussoy P., Lormeau J.C., and Herbert J.M. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 398 (1999) 417-422
16. Salas A., Sans M., Soriano A., Reverter J.C., Anderson D.C., Pique J.M., and Panes J. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 47 (2000) 88-96
17. Watson T., Kakar P., and Lip G.Y. Cardioversion for atrial fibrillation: does inflammation matter?. Am J Cardiol 99 (2007) 1617-1618